Secondary Logo

Antibody Persistence in Australian Adolescents Following Meningococcal C Conjugate Vaccination

Perrett, Kirsten P. MBBS, FRACP, PhD*; Richmond, Peter C. MBBS, MRCP, FRACP; Borrow, Ray PhD, FRCPath; Nolan, Terry BMedSc, MBBS, PhD, FRACP, FAFPHM*; McVernon, Jodie BMedSc, MBBS, PhD, FAFPHM*

The Pediatric Infectious Disease Journal: March 2015 - Volume 34 - Issue 3 - p 279–285
doi: 10.1097/INF.0000000000000541
Vaccine Reports

Background: In Australia, following the introduction of serogroup C meningococcal (MenC) conjugate vaccine for toddlers and catch-up immunization through adolescence, MenC disease incidence plummeted and remains low. However, individual protection following MenC conjugate vaccination, particularly in young children, may be short-lived. We investigated the persistence of MenC serum bactericidal antibody (SBA) titers in adolescents, more than 7 years after a single “catch-up” dose of MenC conjugate vaccine. We also investigated their exposure and susceptibility to meningococcal serogroups A, W and Y.

Methods: MenC SBA titers and Men A, C, W and Y IgG geometric mean concentration were measured in 240 healthy 11- to 16-year-old adolescents. The correlate of protection was an rSBA titer of ≥8.

Results: An rSBA ≥8 was observed in 105 [44% (95% confidence interval {CI}, 37–50%)] of 240 adolescents (mean age, 13.2 years, mean interval since MenC immunization, 8.2 years). The proportion with an rSBA ≥8, geometric mean rSBA titer and geometric mean IgG concentration increased with age, from 22% to 75%, 3.7 to 33.4 and 0.13 to 0.52 μg/mL, in participants who received MenC vaccine at mean age 2.8 to 7.5 years, respectively. Natural acquired antibody to Men A, W and Y was low with IgG geometric mean concentrations of 1.26, 0.38 and 0.47 μg/mL, respectively.

Conclusions: More than half of Australian adolescents have inadequate serological protection against MenC disease and low natural immunity to MenA, W and Y.

Supplemental Digital Content is available in the text.

From the *Vaccine and Immunisation Research Group (VIRGo), Murdoch Childrens Research Institute and Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia, School of Paediatrics and Child Health, University of Western Australia, Telethon Institute for Child Health Research, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; and Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, Greater Manchester, United Kingdom.

Accepted for publication August 08, 2014.

This study was funded by Novartis. Drs Perrett and McVernon are recipients of Research Fellowships from the Australian National Health and Medical Research Council.

Dr Perrett has received travel support from Novartis for conference attendance and presentation of data at international meetings and honoraria from Pfizer for educational lectures. Dr Richmond has received institutional funding for investigator-initiated research from GlaxoSmithKline Biologicals and Merck and received travel support from Pfizer and Baxter to present study data at international meetings. Dr Borrow has performed contract research on behalf of Public Health England for Baxter, GSK, Merck, Novartis, Pfizer, Sanofi Pasteur and Sanofi Pasteur MSD. Drs Perrett, Nolan and McVernon’s institution (MCRI) has received research grants from GSK, Novartis, CSL, Pfizer and Sanofi Pasteur. Dr Nolan has received past payment for a role (now completed) as a member of the independent data and safety monitoring board for GSK’s HPV vaccine. Dr McVernon has been an investigator on vaccine and epidemiological studies sponsored by a range of vaccine manufacturers, and in this role has received support for conference attendance, presentation of data and membership of vaccine advisory boards.

Dr. Richmond has been a member of vaccine advisory boards for Wyeth and CSL Ltd. Dr. Nolan chairs the Australian Government’s Technical Advisory Group on Immunization (ATAGI) and is a member of the World Health Organization Strategic Advisory Group of Experts (SAGE) on Immunization. Dr McVernon is currently a member of ATAGI. The other authors have no conflicts of interest to disclose.

Address for correspondence: Jodie McVernon, Modelling & Simulation Group, Centre for Epidemiology & Biostatistics, Melbourne School of Population and Global Health, Level 5, 207 Bouverie Street, The University of Melbourne, Melbourne, Victoria 3010, Australia. E-mail:

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (

Neisseria meningitidis is a leading cause of meningitis and septicemia globally, with 6 serogroups responsible for most human disease: A, B, C, W, X and Y.1 Over the past century, Australia has experienced both large meningococcal outbreaks and endemic disease. Significant serogroup A meningococcal (MenA) outbreaks occurred in the context of the first and second World Wars, whereas endemic serogroup B (MenB) and C (MenC) disease, peaking in the winter months, has prevailed since the 1950s.2 In the late 1990s, almost in parallel to the United Kingdom, Australia observed an increase in the proportion of cases due to MenC among infants, teenagers and young adults. Accordingly, in 2003, monovalent MenC conjugate vaccine was included into the national immunization program3 as a single dose at 12 months of age, and a catch-up campaign for all children up to 19 years of age. Program success was unequivocally demonstrated with a decline in MenC disease across all ages (including the unimmunized, indicating herd protection) with no corresponding increase in cases due to other serogroups.4

As the UK was the first country to introduce routine MenC vaccination, much has been learned from their experience. Early direct effectiveness estimates of the initial 3-dose infant schedule were promising (over 90%).5 However, cases of clinical vaccine failure indicated that individual protection with an infant only schedule was short-lived.6 Even after the schedule was amended in 2006 to a 2-dose infant priming and second year of life booster (prime-boost schedule) no evidence of improved antibody persistence or superior protection was demonstrated.7,8 These observations raised concerns that protection offered by infant and/or early childhood immunization may not be sufficient to prevent invasive meningococcal disease through the vulnerable period of adolescence and early adulthood9

Surveillance of the phenotype and genotype of cases of meningococcal disease occurs routinely in most developed countries. In both the UK and Australia, there has recently been a modest increase in incidence of serogroup Y meningococcal (MenY) cases. Measurement of natural immunity to other vaccine preventable serogroups (A, W and Y) is vital both to inform appraisal of likely vulnerability to imported strains and to inform national meningococcal vaccine policy.

We measured serum bactericidal antibody (SBA) titers against MenC in 240 adolescents aged 11 to 16 years of age who had received a single catch-up dose of MenC conjugate vaccine in 2003/2004 (when aged between 2 and 8 years) to determine the impact on long-term immunity to MenC disease of this program. We also assessed the geometric mean concentration (GMC) of IgG against meningococcal A, C, W and Y to provide information on exposure and susceptibility to these serogroups in Australian children.

Back to Top | Article Outline


Study Design and Participants

Between June and December 2011, we collected serum from 240 children in Melbourne and Perth who had received a single catch-up dose of MenC vaccine in 2003/2004 (aged between 2 and 8 years). Children were identified through the Australian Childhood Immunization Register as having received 1 of 3 licensed MenC conjugate vaccines: MenC-CRM [A] (Menjugate®, CSL/Novartis Vaccines and Diagnostics); MenC-CRM [B] (Meningitec®, Pfizer Australia) or MenC-TT (NeisVac-C®, Baxter Healthcare). Each MenC vaccine contains 10 mcg of Neisseria meningitidis group C polysaccharide (strain C11) conjugated to either CRM-197 (a non-toxic mutant of diphtheria toxin) [MenC-CRM (A) and MenC-CRM (B)], or tetanus toxoid (MenC-TT). Letters to parents were sent by Medicare Australia.

Potential participants were excluded if they had: received any additional meningococcal vaccines (other than the single catch-up dose of MenC in 2003/2004); a known immunodeficiency or chronic illness; received any blood products including immunoglobulin; a previous meningococcal infection; ever received meningococcal chemoprophylaxis or had antibiotics within the previous 7 days.

Participants’ individual MenC vaccination history (date and brand) was verified from the parent-held child health record book, Australian Childhood Immunization Register, immunization certificate or General Practitioner records. Written informed consent was obtained from a parent and verbal consent from children aged 12 years and above. Following collection of a 5 mL blood sample, participants were offered a single dose of quadrivalent serogroup A, C, W and Y meningococcal (MenACWY) conjugate vaccine (Menveo®, Novartis Vaccines). Menveo is currently licensed in Australia for persons aged 11 years and older. Approval was obtained from ethics committees at the Royal Children’s Hospital (30207A) and Princess Margaret Hospital for Children (1877/EP).

Back to Top | Article Outline

Serological Responses

Assays were performed at Public Health England Vaccine Evaluation Unit, Manchester, United Kingdom, using standard protocols.10 Serum was tested for SBA against the O-acetylated MenC strain C11 (C:16:P1.7-1,1) using baby rabbit complement (rSBA). In a subset of 60% (determined by sampling specimens across the range of titer distributions to assess correlation across a full spectrum of values), assays were repeated using human complement (hSBA). SBA titers were expressed as the final serum dilution in which 50% bacterial killing was observed after 60 minutes.11 The lower limit of detection was a titer of 4. Values below 4 were assigned a value of 2. Serogroup-specific serum IgG antibody concentrations to serogroup A, C, W and Y meningococci were measured by enzyme linked immunosorbent assays with lower limits of detection of 0.08, 0.06, 0.065 and 0.075 μg/mL, respectively.

Back to Top | Article Outline

Statistical Analysis

The primary objective was to determine the proportion who had a MenC rSBA titer of ≥8 (the putative protective threshold)12 more than 7 years after vaccination. It was hypothesized that rSBA titers against MenC would have waned, leaving 50% or more of adolescents without demonstrable protection. A sample size of 240 participants would demonstrate this proportion with 95% confidence intervals (CI) 43.5%, 56.5%. Secondary objectives were to calculate the: proportion with a MenC hSBA titer of ≥413 and ≥8 (in 60% subset); MenC SBA geometric mean titers (GMT) and IgG GMCs against meningococcal serogroups A, C, W and Y. Analysis was conducted on all available data.

We used univariate and multivariate logistic regression to assess the impact of age at MenC immunization, sex of participant and brand of MenC vaccine on achievement of assay titers above the putative protective thresholds rSBA ≥ 812 and hSBA ≥ 4.13 Furthermore, we performed univariate and multivariate linear regression analysis for log rSBA and hSBA titers and MenC IgG concentrations, to examine the influence of the same variables across the full range of assay results. All analyses were carried out using Microsoft Excel® (version 14.3.9) and STATA (StataCorp®, version 11).

Back to Top | Article Outline


Of the almost 7000 families approached, 466 responded, 293 were assessed for eligibility and 53 were excluded. Reasons for exclusion included: no documentation of MenC vaccine, receipt of more than 1 previous MenC vaccine, long-term antibiotics, outside of age group or too busy. All 240 enrolled participants (160 from Melbourne and 80 from Perth) had blood available for analysis. The mean age at enrolment was 13.2 years (range, 11.1–16.8), mean interval as MenC immunization was 8.2 years (standard deviation, ±0.54) and mean age at receipt of MenC vaccine was 5.1 years (range, 2.4–8.8) (Table 1).



Overall in 2003/2004, 189 participants were immunized with MenC-TT, 21 with MenC-CRM [A], 21 with MenC-CRM [B] and for 9 participants no brand of MenC vaccine was recorded (Table 2). The breakdown by type of MenC vaccine used in each location was 117/20/19/4 for Melbourne and 72/1/2/5 for Perth for MenC-TT, MenC-CRM [A], MenC-CRM [B] and Unknown, respectively. MenC-TT recipients were significantly older than those who received MenC-CRM [A] (mean age 5.1 years compared with 4.5 years, linear regression coefficient -0.65 (95% CI: 1.29, 0.00), P = 0.049). At the completion of the study, 231 (96%) of 240 participants received MenACWY conjugate vaccine.



Back to Top | Article Outline

Primary Objective

Overall, more than 7 years following MenC vaccination, 105 [44% (CI: 37–50%)] of 240 adolescents had an rSBA titer ≥ 8 (range, 22–75% in participants who received MenC at mean age 2.8 and 7.5 years, respectively (Table 3; Fig. 1). An rSBA titer ≥ 8 was found in 44 of 134 adolescents (33%), who received MenC vaccine aged 2 to 4 years compared with 61 of 106 adolescents (58%), who received MenC vaccine aged 5 to 8 years.





Back to Top | Article Outline

Secondary Objectives

Overall the MenC rSBA GMT was 11.3 (CI: 8.7–14.8) and ranged from 3.7 to 33.4 in participants who had MenC vaccine at mean age 2.8 and 7.5 years, respectively (Table 3 and Fig., Supplemental Digital Content 1, The MenC rSBA GMT was significantly lower [6.89 (CI: 4.96–9.56)] in adolescents who received MenC vaccine at 2 to 4 years of age compared with those who received MenC vaccine at 5 to 8 years of age [21.20 (CI: 14.0–32.1)] (P < 0.0001).

A MenC hSBA titer ≥ 4 was found in 48 of 140 adolescents [34% (CI: 26–42%)] and a titer ≥ 8 in 39 of 140 adolescents [28% (CI: 20–35%)] (data not shown).

Overall, the MenC IgG GMC was 0.29 μg/mL (CI: 0.25–0.33). Adolescents who received MenC vaccine at 2 to 4 years of age had a significantly lower MenC IgG GMC [0.24 μg/mL (CI: 0.20–0.29)] than adolescents who received MenC vaccine between 5 and 8 years of age [0.37 μg/mL (CI: 0.30–0.45)] (P = 0.0009).

Age at MenC immunization was the only parameter consistently shown to significantly affect the MenC rSBA titer, IgG concentration and proportion with rSBA ≥ 8, both by univariate and multivariate analysis (adjusting for sex of participant and brand of MenC vaccine) (Tables 4 and 5). There were no significant differences in these immune measures by participant sex.





There was a trend (not statistically significant) for those who received a tetanus-toxoid conjugate MenC vaccine (MenC-TT), rather than a CRM-197 conjugate MenC vaccine [MenC-CRM (A) or MenC-CRM (B)] to exhibit higher rSBA titers (rSBA titer and proportion with an rSBA titer ≥ 8) (Table 2). This reached statistical significance for MenC hSBA titers using human complement (hSBA titer and proportion with an hSBA titer ≥ 4) (Table 5).

Men A, W and Y IgG GMCs in the 11- to 16-year-old participants were 1.26, 0.38 and 0.47 μg/mL, respectively, and did not differ by age (data not shown).

Back to Top | Article Outline


Key Findings

This study shows that sustained vaccine-induced immunity to MenC disease during childhood is dependent on age at vaccination. Furthermore, more than half of the current cohort of Australian adolescents may be susceptible to MenC disease. Specifically, only 44% of the 11- to 16-year old in this study had persistent rSBA titers above the serological correlate of protection (rSBA titer of ≥ 8)12 more than 7 years after immunization. Long-term persistence of MenC antibody (rSBA, hSBA and IgG) following early childhood immunization improved with increasing age at primary vaccination (between 2 and 8 years of age). This is also the first study to show that natural immunity to other vaccine-preventable serogroups of meningococci (A, W and Y) is low in 11- to 16-year-old Australian adolescents.

The age-dependent MenC antibody findings of this study concur with previous evidence of poor antibody persistence following MenC vaccination in young children14,15 and improved antibody persistence in older children.16 In our study, only one-third of the adolescents immunized between 2 and 4 years of age had an rSBA titer ≥ 8, compared with almost 60% of adolescents immunized between 5 and 8 years of age. MenC rSBA titers and IgG concentrations followed a similar pattern providing further evidence that immune responses to meningococcal vaccines improve around the age of 5 years14–17 regardless of whether administered as a priming or booster dose.7

Human complement source SBA assays were performed in the original studies of SBA against MenC. A serum dilution ≥ 4 by hSBA is an historical population-level correlate of naturally induced immune protection,13 whereas a serum dilution of ≥ 8 by rSBA allows bridging comparison with population-derived correlates of direct protective efficacy following conjugate vaccine administration.18 Only 34% of adolescents in our study had a MenC hSBA titer ≥ 4 compared with 44% with a rSBA titer ≥ 8. This finding is consistent with previous evaluations of meningococcal correlates of protection that rSBA may give higher titers than hSBA and further, although a rSBA ≤ 8 predicts susceptibility (with high specificity) and a hSBA ≥ 4 indicates protection, a hSBA ≤ 4 does not always indicate susceptibility.11,13

Back to Top | Article Outline

Explanation for Findings

Immunological maturation has emerged as the most compelling explanation for age-dependent MenC antibody responses in childhood. Primary antibody responses to MenC conjugate vaccination are higher in adolescents than in younger children.19 Furthermore, natural decline in circulating MenC SBA titers with time has been shown in infants and likely occurs faster in younger children than adolescents.20 Younger children also appear to be less well primed for a secondary immune response.14 Immature intrinsic germinal center B-cell reactions and suboptimal microenvironmental factors in lymphoid tissue and bone marrow are thought to be some of the mechanisms behind these observations,21 culminating in generation of fewer long-lived plasma cells.22

Back to Top | Article Outline

Strengths and Weaknesses

In contrast to data from meningococcal serosurveys conducted using banked residual sera agnostic to vaccine status in the United Kingdom and the Netherlands;8,17,23,24 this study selectively recruited individuals with a confirmed date and brand of MenC vaccination. This study therefore allowed accurate determination of antibody persistence following MenC immunization in childhood by age and product. The uptake of MenC vaccine in the catch-up group (those aged 2 to 18 years) in Australia between 2003 and 2006 is estimated at 70%.25 Therefore, it is possible that our findings may underestimate the true susceptibility to MenC disease in the current Australian adolescent population.

This study was not powered to look at persistence of the immune response following childhood MenC immunization by brand of vaccine received, so interpretation of this analysis is limited due to the small sample size of adolescents primed with either of the MenC-CRM vaccines. Our data suggested a trend for better persistence following receipt of the MenC-TT tetanus toxoid conjugate MenC vaccine than either of the CRM conjugates for rSBA and statistically significantly by hSBA. Other studies have found superior immune responses following primary vaccination with the MenC-TT vaccine than either of the MenC-CRM vaccines.7,19 Larger cohort studies following recipients of alternative MenC vaccines would be required to make definitive conclusions regarding the influence of conjugate protein type on long-term persistence of MenC antibody in childhood.

Despite the strongly significant age-dependent antibody findings of this study, the MenC rSBA GMT and proportion with rSBA titer ≥ 8 were lower (nonstatistically significant) in the children immunized with MenC at 8 years compared with 7 years of age. This is likely due to the small sample size in the older age group (resulting in very wide CI), and limits the accuracy of the data for that age. Accordingly, for both age groups with small sample sizes (2 and 8 years of age) data was combined with the adjacent age group in Figure 1.

This study also indicates that the current cohort of Australian adolescents may be susceptible to other meningococcal serogroups. Although no definitive surrogate of protection has been defined for serogroups A, W or Y, IgG concentrations can be informative. MenW and Y IgG antibody concentrations were low and showed little variation by age in the 11- to 16-year-old adolescents. A recent seroprevalence study of MenW and Y rSBA in England also found natural immunity to be low particularly in young children, with no rise in adolescence. Instead, peak titers to these strains were observed in 20- to 24-year olds (W-135) and 30- to 44-year olds (Y).24 Historically, serogroup Y disease has been rare in the United Kingdom and Australia, but recently such cases have more than doubled both in the United Kingdom (from 29 in 2007/2008 to 81 in 2011/2012, an increase from 2% to 11% of all meningococcal cases)26,27 and in Australia (from 7 in 2008 to 15 in 2011, a rise from 2.8% to 7.0% of all cases).28,29 Therefore, the low levels of natural immunity to serogroup Y are of some concern. Furthermore, a recent study in university students in Nottingham, United Kingdom, found carriage rates of MenY have increased dramatically from 5% in 1999–200130 to up to 25% in 200931,32 suggesting MenY circulation in the United Kingdom may be increasing. No such Australian adolescent carriage studies have been performed. In our study, serogroup A IgG levels were higher than for MenW or Y despite no evidence of circulation in Australia.28 Similar seroprevalence findings were reported in the United Kingdom.23 These higher MenA concentrations may be attributable to the presence of cross-reacting antigens.33–35

Back to Top | Article Outline

Clinical Relevance

In accordance with predictions, aging cohorts of children immunized with MenC vaccine in infancy and early childhood has been associated with an overall increase in the pool of apparently susceptible older children and adolescents.14,36 Serial UK seroprevalence studies show that the high levels of MenC immunity observed in 10- to 19-year olds in 2000–2004, representing those eligible for catch-up vaccination during primary and secondary school,23 persisted as they aged into the 15- to 24-year old group by 2009, 10 years following the catch-up campaign.8 In that same year, however, less than 30% of UK children aged from 1 to 14 years had persistent MenC SBA titers ≥ 8. These lower levels of seroprotection in the early teenage cohort in 2009 raise concerns that herd immunity, the predominant mechanism of disease control at present, will decline as catch-up cohorts continue to age.37 Accordingly, over the next 10 years, the likelihood of re-establishment of endemic transmission of imported strains will inevitably increase.

Although we did not measure persistence of immunity in children who had been immunized at the routine Australian MenC vaccination time-point of 12 months, our antibody results were strongly age-dependent. More than 7 years following MenC vaccination, only 22% of our youngest study participants (mean age at receipt of MenC, 2.8 years) had an rSBA titer ≥ 8, suggesting that the proportion of children with titers considered protective after receipt of MenC vaccine at 12 months would be even lower. Recently, a study of antibody persistence 5 years following either a single dose of combined Haemophilus influenzae type b-MenC or monovalent MenC conjugate vaccines at 12 to18 months of age reported only 19% and 25% of children, respectively, had an rSBA titer ≥ 8, similar levels to our study.38 We predict that by 2015, less than 1 in 5 Australian children entering adolescence (12 years of age) will have MenC rSBA titers sufficient for protection against MenC disease.

Circulation of MenC in Australia is currently low (only 11 laboratory-confirmed cases in 2012)39 and comparable to cases of W and Y (7 and 15 cases in 2012 respectively).39 By this measure alone, introduction of an adolescent meningococcal booster (MenC or MenACWY) may not be justified at this time. However in 2012, 3 cases of MenC disease occurred in the immunized cohort (15 to 24 years of age)39 and at least 5 cases of vaccine failure have occurred in children since the introduction of MenC vaccine in Australia (personal communication). What is not yet known, but critical for a formal cost–effectiveness evaluation of routine adolescent meningococcal vaccination in Australia, is the rate of carriage of circulating strains in adolescents and young adults (the major transmitters of disease in the pre-vaccine era). If the rate of endemic transmission is increasing in this cohort, as predicted with low levels of seroprotection, herd immunity (a significant component of the effectiveness of MenC vaccines) will decrease. In addition, even with appropriate antibiotics, meningococcal disease progresses rapidly resulting in an often devastating and potentially fatal course. Accordingly, due to the risk of a return to pre-vaccine disease patterns in adolescents, a preemptive adolescent booster meningococcal strategy in Australia should be considered. The dual benefit of this strategy is direct protection to the immunized adolescent going into the secondary peak risk period in the late teen years and early twenties and also indirect protection of these emergent parents to infants. In the United Kingdom, with the considerable MenC disease outbreak of the early 2000s still in recent memory, a preemptive adolescent MenC vaccine strategy has commenced.40 A catch-up campaign was implemented for all new starters at universities up to the age of 25 years.40 In the US, the incidence of meningococcal disease has declined among all age groups and in all vaccine-related serogroups since a single-dose of MenACWY conjugate vaccine was recommended at 11–12 years of age in 2005.41 Recently, the Advisory Committee on Immunization Practices (ACIP) revised the recommendation to a 2-dose strategy to optimize meningococcal protection through late adolescence into early adulthood.42

Our study has revealed both the current and potential future susceptibility of Australian adolescents to serogroups A, C, W and Y, and provides new evidence to inform considerations of meningococcal vaccine schedule requirements.

Back to Top | Article Outline


The authors are grateful to the participants of this study and their family members. The authors thank the contributions of the staff members of the Vaccine and Immunisation Research Group (Melbourne), Marita Kefford, Sharon Trevorrow, Mairead Phelan, Annmarie McEvoy, Jane Ryrie, Clare Brophy, Janet Briggs, Marie West, Jacinta Sonego, Jacinta O’Keefe, Judith Spotswood, Paula Nathan and Bernie McCudden; Caroline Talbot and Jennifer Kent of the Vaccine Trials Group (Perth); and Drs Helen Findlow and Xilian Bai of the Public Health England Vaccine Evaluation Unit (Manchester, United Kingdom).

Back to Top | Article Outline


1. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–2210
2. Patel MS. Australia’s century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med J Aust. 2007;186(3):136–141
3. Booy R, Jelfs J, El Bashir H, Nissen M. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust. 2007;186(3):108–109
4. Tapsall J. Annual report of the Australian meningococcal surveillance programme, 2007 - amended. Comm Dis Intell. 2009;33(1):1–9
5. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365–366
6. Trotter C, Andrews N, Kaczmarski E, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365–367
7. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154–159
8. Ishola DA Jr, Borrow R, Findlow H, et al. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol. 2012;19(8):1126–1130
9. Trotter C, Borrow R, Findlow J, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vacc Immunol. 2008;15(11):1694–1698
10. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4(2):156–167
11. Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69(3):1568–1573
12. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10(5):780–786
13. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326
14. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 2010;50:1601–1610
15. Snape MD, Kelly DF, Green B, et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24(2):128–131
16. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ. 2008;336(7659):1487–1491
17. de Voer RM, Mollema L, Schepp RM, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS One. 2010;5:e12144
18. Arguedas A, Soley C, Loaiza C, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine. 2010;28:3171–3179
19. Burrage M, Robinson A, Borrow R, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun. 2002;70(9):4946–4954
20. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364(9431):365–367
21. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev. 2009;9(3):185–194
22. Perrett KP, Jin C, Clutterbuck E, et al. B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody. J Immunol. 2012;189:2673–2681
23. Trotter CL, Borrow R, Findlow J, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol. 2008;15:1694–1698
24. Trotter CL, Findlow H, Borrow R. Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009. Clin Vaccine Immunol. 2012;19:219–222
25. . Meningococcal vaccines for Australians. NCIRS Fact Sheet. 2009 Accessed June 20, 2013
26. . Health Protection Agency U. Invasive meningococcal infections laboratory reports, England and Wales by capsular group & epidemiological year, 1998/99–2011/12. 2012 Accessed 20 June, 2013
27. Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30:3710–3716
28. Lahra MM, Enriquez RP. Annual report of the Australian Meningococcal Surveillance Programme, 2011. Commun Dis Intell Q Rep. 2012;36:E251–E262
29. Tapsall J. Annual report of the Australian Meningococcal Surveillance Programme, 2008. 2009;33(3):259–267
30. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–743
31. Ala’aldeen DA, Oldfield NJ, Bidmos FA, et al. Carriage of meningococci by university students, United Kingdom. Emerg Infect Dis. 2011;17(9):1762–1763
32. Bidmos FA, Neal KR, Oldfield NJ, et al. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol. 2011;49(2):506–512
33. Guirguis N, Schneerson R, Bax A, et al. Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. J Exp Med. 1985;162(6):1837–1851
34. Myerowitz RL, Gordon RE, Robbins JB. Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A. Infect Immun. 1973;8(6):896–900
35. Robbins JB, Myerowitz L, Whisnant JK, et al. Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun. 1972;6(5):651–656
36. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev. 2009;9(3):213–220
37. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840–847
38. Booy R, Nolan T, Reynolds G, et al. Immunogenicity and safety of the Hib-MenC-TT conjugate vaccine in Hib-primed toddlers: 5 year follow-up.
39. Lahra MM, Enriquez RP. Australian Meningococcal Surveillance Programme annual report, 2012. 2013;37(3):E224–232
40. England PH. Changes to the Meningococcal C conjugate (MenC) vaccine schedule 2013. 2013 https:// Accessed June 28, 2013
41. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1–21
42. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28

Neisseria meningitidis; monovalent serogroup C meningococcal vaccine; persistence of immunity; immunization; adolescence

Supplemental Digital Content

Back to Top | Article Outline
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.